Inspire Advisors LLC Acquires Shares of 47,130 OPKO Health, Inc. (NASDAQ:OPK)

Inspire Advisors LLC purchased a new stake in OPKO Health, Inc. (NASDAQ:OPK) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 47,130 shares of the biotechnology company’s stock, valued at approximately $78,000.

Several other large investors have also modified their holdings of the stock. Oak Thistle LLC purchased a new stake in shares of OPKO Health in the 1st quarter worth about $26,000. Cerity Partners LLC purchased a new position in shares of OPKO Health in the 1st quarter worth $36,000. Wealth Enhancement Advisory Services LLC grew its holdings in shares of OPKO Health by 75.3% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 12,417 shares during the period. Pallas Capital Advisors LLC acquired a new position in shares of OPKO Health during the first quarter worth about $43,000. Finally, Zacks Investment Management purchased a new position in OPKO Health in the 4th quarter worth approximately $49,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

Analyst Ratings Changes

OPK has been the subject of a number of research analyst reports. Barrington Research restated an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a research note on Thursday, May 1st. LADENBURG THALM/SH SH raised shares of OPKO Health to a “strong-buy” rating in a report on Tuesday, July 8th. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a report on Monday, April 7th. Wall Street Zen cut shares of OPKO Health from a “hold” rating to a “sell” rating in a research note on Monday, May 5th. Finally, JPMorgan Chase & Co. started coverage on shares of OPKO Health in a report on Friday, April 25th. They set a “neutral” rating on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, OPKO Health currently has a consensus rating of “Moderate Buy” and an average target price of $2.75.

OPKO Health Stock Performance

OPK opened at $1.35 on Wednesday. The company has a current ratio of 2.49, a quick ratio of 2.28 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $1.07 billion, a PE ratio of -19.28 and a beta of 1.34. The firm has a 50-day moving average price of $1.34 and a two-hundred day moving average price of $1.48. OPKO Health, Inc. has a 1-year low of $1.21 and a 1-year high of $2.04.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.03). OPKO Health had a negative return on equity of 2.85% and a negative net margin of 5.66%. The business had revenue of $149.90 million during the quarter, compared to the consensus estimate of $163.13 million. During the same quarter last year, the company earned ($0.12) earnings per share. The firm’s revenue was down 13.7% compared to the same quarter last year. As a group, equities analysts anticipate that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.